Stock Detail
TENGION INC
Biotechnology
TNGN @ Yahoo Finance | TNGN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.59 | $0.63 | $0.04 | 8.26% | 0.00 | $0.55 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.55 | $0.50 | 298,824 | 14.05M | 132,975.5 | -1.07 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.70 | 0.64 | 0.57 | 0.51 | 0.44 |
Stock Profile
Tengion, Inc., a regenerative medicine company, focuses on discovering, developing, manufacturing, and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. It creates these functional neo-organs and neo-tissues using a patientÂ's own cells, or autologous cells, in conjunction with the companyÂ's Organ Regeneration Platform. The companyÂ's lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The company was founded in 2003 and is headquartered in East Norriton, Pennsylvania.